BioCardia (BCDA) Projected to Announce Earnings on Monday

BioCardia (NASDAQ:BCDA) is projected to post its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect BioCardia to announce earnings of ($0.19) per share for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

BioCardia (NASDAQ:BCDA) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). On average, analysts expect BioCardia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioCardia Price Performance

Shares of NASDAQ:BCDA traded up $0.03 during trading on Monday, reaching $0.86. The company had a trading volume of 6,108 shares, compared to its average volume of 1,374,700. BioCardia has a fifty-two week low of $0.75 and a fifty-two week high of $2.29. The firm has a market capitalization of $9.75 million, a price-to-earnings ratio of -0.94 and a beta of 0.44. The stock’s fifty day moving average price is $0.94 and its 200 day moving average price is $1.11.

Analysts Set New Price Targets

BCDA has been the topic of several research reports. Wall Street Zen upgraded shares of BioCardia to a “sell” rating in a report on Saturday, July 18th. Zacks Research lowered BioCardia from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a research report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of BioCardia in a research report on Tuesday, June 9th. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $25.00.

Insider Activity at BioCardia

In other BioCardia news, Director Simon H. Stertzer purchased 70,200 shares of the business’s stock in a transaction dated Monday, June 22nd. The shares were bought at an average price of $0.92 per share, with a total value of $64,584.00. Following the completion of the acquisition, the director owned 127,338 shares in the company, valued at approximately $117,150.96. This represents a 122.86% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have bought a total of 145,900 shares of company stock worth $137,212 in the last three months. 17.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioCardia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cetera Investment Advisers acquired a new position in BioCardia during the second quarter worth about $40,000. DRW Securities LLC acquired a new position in shares of BioCardia in the 4th quarter worth approximately $72,000. Finally, Geode Capital Management LLC grew its stake in shares of BioCardia by 70.4% in the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after purchasing an additional 27,263 shares during the last quarter. Institutional investors own 20.57% of the company’s stock.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.